Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a ...
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...
In addition, Olema has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and ...
Olema Pharmaceuticals stock surged 197% after Roche reported positive trial results for a similar breast cancer drug.
1d
Olema Pharmaceuticals Has Nearly Tripled on Cancer Drug Hopes. How Should You Play OLMA Stock Here?
Olema stock soared Tuesday after Roche reported strong clinical results for its breast cancer drug. An Oppenheimer analyst sees significant further upside in OLMA shares to $45.
OLMA stock surged 197% after Roche’s SERD breakthrough, signaling investor conviction in the future of ER-positive breast ...
Olema Pharmaceuticals (OLMA) surges after Roche's breast cancer data, but caution is urged as key clinical results are ...
Stocktwits on MSN
Novartis Stock Softens Premarket Even As It Raises 2030 Outlook, Sales Guidance For Two Key Cancer Drugs
Novartis raised peak sales targets for Kisqali and Scemblix, adding to its roster of multi-billion-dollar oncology drugs.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) shares are popping on Monday following the company's positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with ...
We recently published 10 Firms Shining Bright in a Bleeding Market. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the best ...
Key Takeaways Abbott Laboratories has agreed to acquire Exact Sciences Corp. in a deal worth $21 billion, paying shareholders $105 per share.Exact Sciences makes a variety of cancer screening tests, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback